AMG 655 and AMG 479 investigated with gemcitabine for metastatic pancreatic cancer efficacy
Background
Advanced pancreatic adenocarcinoma (PDAC) remains a highly aggressive malignancy with poor prognosis, often diagnosed at a metastatic stage. Current first-line treatment options, such as gemcitabine-based regimens, offer limited survival benefits, especially for elderly patients or those with significant comorbidities. There is an urgent clinical need for novel therapeutic strategies that can improve efficacy and extend survival. This study explores the potential of combining investigational agents AMG 655 and AMG 479 with standard-of-care gemcitabine to address this critical gap in metastatic pancreatic cancer treatment.
Study Design
This multi-center, 2-part clinical trial investigates AMG 655 or AMG 479 in combination with gemcitabine as first-line treatment for subjects with metastatic pancreatic cancer. Part 1, an open-label Phase 1b dose-escalation segment, aimed to determine the safety, tolerability, and maximum tolerated dose (MTD) of AMG 655 alongside gemcitabine. Following dose selection from Part 1, Part 2 will commence as a randomized, placebo-controlled Phase 2 segment. In Part 2, subjects will be randomized 1:1:1 to receive AMG 655, AMG 479, or AMG 655-placebo, all in combination with gemcitabine. The primary endpoint for Part 2 is to estimate the efficacy as assessed by 6-month survival.
Results
As of the abstract's publication, enrollment into Part 1 (the open-label, dose-escalation Phase 1b segment) of the study has been completed. However, the abstract does not present any specific safety, tolerability, or MTD results from Part 1. Consequently, no efficacy data or specific findings regarding the combination of AMG 655 or AMG 479 with gemcitabine are available at this stage. The Phase 2 segment, which is designed to assess efficacy via 6-month survival, is slated to commence only after the dose selection process from Part 1 has been finalized. Therefore, the study is currently in an investigational phase, with no reported clinical outcomes or statistical data.
The abstract explicitly states that Part 1 enrollment is complete, but no results from this phase are provided, and Part 2 has not yet begun.
Key Findings
- Study is a multi-center, 2-part design (Phase 1b/2) for metastatic pancreatic cancer.
- Part 1 (Phase 1b) is an open-label, dose-escalation segment to determine safety, tolerability, and MTD of AMG 655 + gemcitabine.
- Enrollment for Part 1 has been completed, but no results are reported.
- Part 2 (Phase 2) will be randomized, placebo-controlled, 1:1:1, assessing 6-month survival.
- Part 2 will compare AMG 655, AMG 479, or placebo, all with gemcitabine.
Why It Matters
If successful, this study could introduce a new first-line treatment option for metastatic pancreatic cancer, a disease with notoriously poor prognosis. The combination of novel agents AMG 655 or AMG 479 with gemcitabine aims to improve upon current standard-of-care regimens, potentially extending 6-month survival rates. For clinicians, this represents a crucial step towards expanding the therapeutic arsenal against this aggressive cancer. While no results are yet available, the study design sets the stage for potentially identifying a more effective and tolerable regimen, which could significantly impact patient outcomes and quality of life in a population with limited options. The determination of an MTD in Part 1 is essential for establishing a safe and viable dosing protocol for future clinical use.
pancreatic-cancer
metastatic-cancer
clinical-trial
phase-1b
phase-2
gemcitabine